July 11, 2013

Theratechnologies obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI

Theratechnologies Inc. (TSX: TH) today announced that the US Patent and Trademark Office (USPTO) has issued Patent No. 8,481,489 entitled “GH Secretagogues and Uses Thereof” covering a method of improving cognitive function in a subject suffering from mild cognitive impairment (MCI) through the administration of tesamorelin. The patent will expire in 2024.